CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to RHHBY

Phase 3

Development Phase

1

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

Upcoming Catalysts
What are catalysts?
5mo
RHHBYPDUFA
Phase 3

FDA PDUFA Date Lunsumio VELO (mosunetuzumab) in combination with Polivy (polatuzumab vedotin) (accelerated review)

Mosunetuzumab
Feb 9STALE
Source
00%
Competitive Landscape

1 competitor in Non-Hodgkin Lymphoma

View Full Landscape
Drug Information

Target Indication

Non-Hodgkin Lymphoma

Clinical Trial

NCT05171647

Last updated: 2/9/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.